HODGKIN LYMPHOMA

This early-phase study tests a new treatment for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. The approach uses a person's own immune cells, modified to attack cancer cells, along with specially edited stem cells to he…

This study tests whether adding nivolumab to standard chemotherapy (AVD) can safely control early-stage Hodgkin lymphoma in patients aged 2 to 21. The goal is to see if the combination works better than chemo alone. About 15 participants will receive the treatment and be monitore…

This early-phase trial tests a new type of immune cell therapy for people with certain blood cancers that have not responded to standard treatments. The therapy uses specially engineered natural killer (NK) cells from donated cord blood, designed to better target cancer cells and…

This study is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control advanced cancers that have spread or cannot be removed by surgery. The goal is to see if this cheaper, simpler approach works as well as the standard dose, which co…

This study tests a new treatment using specially engineered immune cells (CD70.CAR NK cells) for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to initial therapy or came back within a year. The goal is to see if these cells can safely control …

This study looks at whether people with early-stage Hodgkin lymphoma who respond well to two cycles of chemotherapy can safely receive a lower dose of radiation (20 Gy instead of the usual 30 Gy). About 518 adults will take part. The goal is to see if the lower dose works just as…

This study looks at whether taking extra CT or MRI scans during proton therapy can help doctors adjust the treatment plan for children with solid tumors or Hodgkin's lymphoma. About 100 children will get weekly or every-other-week scans to check if the tumor or nearby organs have…